Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
0(0%)
Results Posted
20%(2 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_1
8
67%
Ph phase_2
4
33%

Phase Distribution

8

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
8(66.7%)
Phase 2Efficacy & side effects
4(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(10)
Terminated(2)

Detailed Status

Completed10
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 18 (66.7%)
Phase 24 (33.3%)

Trials by Status

completed1083%
terminated217%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT04471337Phase 1

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

Completed
NCT04614246Phase 2

Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb

Terminated
NCT04265781Phase 1

Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants

Completed
NCT04487431Phase 1

A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)

Completed
NCT03310645Phase 1

Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients

Completed
NCT04454424Phase 1

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

Completed
NCT04545580Phase 2

Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB)

Completed
NCT04641273Phase 2

A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain

Terminated
NCT04802343Phase 1

A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men

Completed
NCT04562155Phase 2

Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough

Completed
NCT04423744Phase 1

Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants

Completed
NCT02817100Phase 1

First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY1817080

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12